

Neuropathic Pain - Pipeline Review, H2 2019

https://marketpublishers.com/r/N8DC6078A19EN.html

Date: December 2019

Pages: 838

Price: US\$ 2,500.00 (Single User License)

ID: N8DC6078A19EN

Abstracts

Neuropathic Pain - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key



players involved in therapeutic development for Neuropathic Pain (Neuralgia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 21, 46, 45, 1, 4, 157, 30 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 34 and 2 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.



Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Neuropathic Pain (Neuralgia) - Overview

Neuropathic Pain (Neuralgia) - Therapeutics Development

Neuropathic Pain (Neuralgia) - Therapeutics Assessment

Neuropathic Pain (Neuralgia) - Companies Involved in Therapeutics Development

Neuropathic Pain (Neuralgia) - Drug Profiles

Neuropathic Pain (Neuralgia) - Dormant Projects

Neuropathic Pain (Neuralgia) - Discontinued Products

Neuropathic Pain (Neuralgia) - Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by 1st Bio Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Abalone Bio Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Achelios Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Acorda Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Adynxx Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AfaSci Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Affectis Pharmaceuticals AG, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Akelos Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Algomedix Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Alion Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Allergan Plc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Allodynic Therapeutics LLC, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AlphaNavi Pharma Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Amgen Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AnaBios Corp, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Anavex Life Sciences Corp, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Angelini Group, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AngioChem Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Anida Pharma Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AnyGen Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AOBiome LLC, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Aoxing Pharmaceutical Company Inc, H2

2019

Neuropathic Pain (Neuralgia) - Pipeline by APT Therapeutics Inc, H2 2019



Neuropathic Pain (Neuralgia) - Pipeline by Aptarion biotech AG, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Aptinyx Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Araim Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Arena Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Artelo Biosciences Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Asahi Kasei Pharma Corp, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Asarina Pharma AB, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Astellas Pharma Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Astraea Therapeutics LLC, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AstraZeneca Plc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by AusCann Group Holdings Ltd, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Avanir Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) - Pipeline by Avilex Pharma ApS, H2 2019



List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

1st Bio Therapeutics Inc

Abalone Bio Inc

Achelios Therapeutics Inc

Acorda Therapeutics Inc

Adynxx Inc

AfaSci Inc

Affectis Pharmaceuticals AG

Akelos Inc

Algiax Pharmaceuticals GmbH

Algomedix Inc

Alion Pharmaceuticals Inc

Allergan Plc

Allodynic Therapeutics LLC

AlphaNavi Pharma Co Ltd

Amgen Inc

AnaBios Corp

Anavex Life Sciences Corp

Andros Pharmaceuticals Co Ltd

Angelini Group

AngioChem Inc

Anida Pharma Inc



AnyGen Co Ltd

AOBiome LLC

Aoxing Pharmaceutical Company Inc

APT Therapeutics Inc

Aptarion biotech AG

Aptinyx Inc

Aquilus Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Asahi Kasei Pharma Corp

Asarina Pharma AB

Astellas Pharma Inc

Astraea Therapeutics LLC

AstraZeneca Plc

Astrocyte Pharmaceuticals Inc

AusCann Group Holdings Ltd

Avanir Pharmaceuticals Inc

Avilex Pharma ApS

Axsome Therapeutics Inc

BCI Pharma SA

Bioasis Technologies Inc

Biodol Therapeutics SAS

BioElectron Technology Corp

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Bioiberica SAU

Blackthorn Therapeutics Inc

Bol Pharma

Bsense Bio Therapeutics Ltd

Calchan Ltd

Cara Therapeutics Inc

Cavion LLC

CCH Pharmaceuticals ApS

CDA Research Group Inc

Celgene Corp

Cellatoz Therapeutics Inc

Centrexion Therapeutics Corp



Cerecin Inc

Cerecor Inc

CerSci Therapeutics Inc

Charleston Laboratories Inc

Chromocell Corp

Circuit Therapeutics Inc

Citragen Pharmaceuticals Inc

Cleveland Diabetes Care Inc

Clexio Biosciences Ltd

Coda Biotherapeutics Inc

Corium International Inc

Crossject SA

Cryno LLC

CrystalGenomics Inc

Curatis AG

CURx Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daya Drug Discoveries Inc

DelNova Inc

Dompe Farmaceutici SpA

Eicosis LLC

Eli Lilly and Co

EnhanX Biopharm Inc

Epalex Corp

Exodos Life Sciences Limited Partnership

Expression Drug Designs LLC

Exxel Pharma Inc

Four Chuankeruide Pharmaceutical Co Ltd

GABA Therapeutics Inc

GB Sciences Inc

Glialogix Inc

Grace Therapeutics LLC

Grunenthal GmbH

GW Pharmaceuticals Plc

H. Lundbeck AS

Hana Pharm Co Ltd

Helixmith Co Ltd

Hoba Therapeutics ApS



ICE Therapeutics Ltd

Ichnos Sciences Inc

Imbrium Therapeutics LP

Immune Pharmaceuticals Inc

Impel NeuroPharma Inc

Initiator Pharma AS

InKemia IUCT Group SA

InMed Pharmaceuticals Inc

InStar Technologies AS

Intec Pharma Ltd

Integral Molecular Inc

IntelGenx Corp

Intellipharmaceutics International Inc

Invisio Ltd

Ionis Pharmaceuticals Inc

Ipsen SA

iQure Pharma Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

JT Pharmaceuticals Inc

Kancera AB

KannaLife Sciences Inc

Kineta Inc

Klaria Pharma Holding AB

Knopp Biosciences LLC

Kolon Life Science Inc

Komipharm International Co Ltd

Krisani Bio Sciences Pvt Ltd

Lateral Pharma Pty Ltd

Lexicon Pharmaceuticals Inc

Living Cell Technologies Ltd

Lohocla Research Corp

Luye Pharma Group Ltd

MannKind Corp

Mapi Pharma Ltd

MD Biosciences GmbH

Medifron DBT Co Ltd

MEDRx Co Ltd



Medytox Inc

Merck & Co Inc

Merz Pharma GmbH & Co KgaA

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Mundipharma International Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeurAxon Pharma Inc

Neurim Pharmaceuticals Ltd

Neuro Vigor LLC

NeuroCycle Therapeutics GmbH

Neurodyn Life Sciences Inc

NeuroFix Therapeutics LLC

Neurona Therapeutics Inc

NeurOp Inc

NeuroPn Therapeutics LLC

NeuroTherpia Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

NoNO Inc

Novaremed AG

Novassay SA

Noveome Biotherapeutics Inc

NutriBand Inc

OKYO Pharma Ltd

Old API Wind-down Ltd

OliPass Corporation

OliX Pharmaceuticals Inc

Orexigen Therapeutics Inc

OWP Pharmaceuticals Inc

Panag Pharma Inc

Panaxia Pharmaceutical Industries Ltd

Paracelsus Neuroscience I LLC

Patagonia Pharmaceuticals LLC

Pharmaleads SA

Pharmnovo AB

Phosphagenics Ltd



Pivot Pharmaceuticals Inc

PixarBio Corp

PlantForm Corp

Priavoid GmbH

PRISM Pharma Co Ltd.

Promius Pharma LLC

ProNeurogen Inc

Qingdao Chia Tai Haier Pharmaceutical Co Ltd

RAFT Pharmaceuticals

RaQualia Pharma Inc

Re-Pharm Ltd

Regeneus Ltd

Relieve Genetics Inc

Revance Therapeutics Inc

Romark Laboratories LC

Rottapharm Biotech Srl

Saniona AB

Sarfez Pharmaceuticals Inc.

Satsuma Pharmaceuticals Inc

Scientus Pharma Inc

Scilex Holding Co

Serentrix LLC

Seurat Therapeutics Inc

Shanghai Junshi Bioscience Co Ltd

Shanghai SIMR Biotech Co Ltd

Shenox Pharmaceuticals LLC

Shin Nippon Biomedical Laboratories Ltd

Shionogi & Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Signal Pharma Ltd

Sollis Therapeutics Inc

Sorrento Therapeutics Inc

Sosei Heptares

SpineThera Inc

Stem Cell Medicine Ltd

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Synerkine Pharma BV

Syntrix Biosystems Inc



Techfields Pharma Co Ltd

Terran Biosciences Inc

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Titan Pharmaceuticals Inc

Topical Innovations BV

Toray Industries Inc

Trevena Inc

TrioxBio Inc

Vertex Pharmaceuticals Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Winston Pharmaceuticals Inc

Xalud Therapeutics Inc

Xoc Pharmaceuticals Inc

Yantai YenePharma Co Ltd

Yooyoung Pharm Co Ltd

Yuhan Corp

Zosano Pharma Corp



I would like to order

Product name: Neuropathic Pain - Pipeline Review, H2 2019

Product link: https://marketpublishers.com/r/N8DC6078A19EN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N8DC6078A19EN.html